Praxis Precision Medicines (PRAX) Net Margin (2023 - 2024)
Praxis Precision Medicines' (PRAX) quarterly Net Margin came in at 3782.07% in Q4 2024, up 3666570.0% year-on-year from N/an in Q1 2024, and up 83.26% quarter-over-quarter from 22593.71% in Q3 2024.
Praxis Precision Medicines (PRAX) Net Margin (2023 - 2024) Analysis & Trends
Praxis Precision Medicines' Net Margin history runs 2 years deep, the most recent figure standing at 3782.07% for Q4 2024.
- On a quarterly basis, Net Margin rose 3666570.0% year-over-year to 3782.07% in Q4 2024; TTM through Sep 2025 was 7008.09%, a 1616281.0% increase from a year earlier, with the FY2024 full-year figure at 4892.65%, up 764875.0% from the prior year.
- Net Margin improved to 3782.07% in Q4 2024 per PRAX's latest filing, from 22593.71% in the prior quarter.
- Across five years, Net Margin topped out at 3782.07% in Q4 2024 and bottomed at 40447.77% in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Praxis Precision Medicines | 8.98 Bn | 8.20 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -3,782.07% |
| Sep 30, 2024 | -22,593.71% |
| Jun 30, 2024 | -11,001.12% |
| Mar 31, 2024 | -13,011.60% |
| Dec 31, 2023 | -40,447.77% |
| Sep 30, 2023 | -5,499.57% |
| Jun 30, 2023 | -4,482.59% |
| Mar 31, 2023 | -5,557.83% |